Keros Doses First Patient in Phase 2 DMD Trial of Rinvatercept
KROS sits 21% above its 52-week low of $9.69.
Summary
Keros has dosed the first patient in its Phase 2 trial of rinvatercept for Duchenne muscular dystrophy (DMD). This is a key pipeline milestone for the company's lead neuromuscular candidate, with initial data expected in the first half of 2027. The trial is an open-label, multi-cohort basket study in late-ambulatory and early non-ambulatory DMD patients, focusing on safety and tolerability with secondary endpoints including functional improvements. This follows the Phase 3 ELRi trial dosing that triggered a $20M Takeda milestone in July, and the company's recent $5M buyback authorization and $350M shelf registration. The DMD program represents a significant expansion opportunity beyond the lead elritercept program in myelodysplastic syndromes and myelofibrosis.
At the time of this announcement, KROS was trading at $11.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $230.4M. The 52-week trading range was $9.69 to $22.55. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.